Eli Lilly (LLY)

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference. Bill Peters, chief financial officer of Amphastar

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.

The worst might be in the rearview mirror.

Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co...

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity.

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

It's important to look beyond near-term volatility.

The weight loss drug market is on track to reach almost $100 billion.

GoodRx (GDRX) Q1 2026 Earnings Call Transcript

Omada Health (OMDA) Q1 2026 Earnings Transcript

The competition is far behind.

Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D

Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug?

IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Mounjaro generated $8.66 billion in sales in the first quarter.

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments.